Профилактика тромботических осложнений у пациентов с инфарктом миокарда, ишемическим инсультом или окклюзией периферических артерий. В комбинации с АСК для профилактики тромботических осложнений при остром коронарном синдроме: с подъемом сегмента ST при возможности проведения тромболитической терапии; без подъема сегмента ST (нестабильная стенокардия, инфаркт миокарда без зубца Q), в т.ч. у больных, подвергающихся стентированию.

CLOPIDOGREL BISULFATE

Clopidogrel is indicated for the prevention of atherothrombotic events as follows : * Recent MI Recent stroke or Established peripheral arterial disease : - Patients suffering from myocardial infarction (from a few days until less than 35 days ) - ischaemic stroke ( from 7 days until less than 6 months) or established peripheral arterial disease. - For patients with a history of recent myocardial infarction (MI) recent stroke or established peripheral arterial disease - Clopidogrel has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not) new MI (fatal or not) and other vascular death. * Acute coronary syndrome: - For patients with acute coronary syndrome [Non-ST segment elevation acute coronary syndrome (unstable angina/non-Q-wave MI) or ST segment elevation acute myocardial infarction ] in combination with ASA in medically treated patients eligible for thrombolytic therapy and those who are to be managed with percutaneous coronary intervention (with or without stent) or CABG Clopidogrel has been shown to decrease the rate or a combined endpoint of cardiovascular death MI stroke or refractory ischemia.